Adicet presents ADI-270 preclinical data at ASGCT; IND filing expected Q2 2024

Adicet Bio, Inc.

ADI-270 is an allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.
Preclinical data showed potent regression in ccRCC xenografts and lower CRS potential vs αβ CAR-T.
Armoring includes TGFβ receptor II inactivation and protection against alloreactive T cells.
IND submission in clear cell renal cell carcinoma (ccRCC) expected Q2 2024.
ADI-270 demonstrated both CAR-dependent and CAR-independent tumor targeting mechanisms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.